{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T01:02:49Z","timestamp":1768438969279,"version":"3.49.0"},"reference-count":36,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,7,18]],"date-time":"2023-07-18T00:00:00Z","timestamp":1689638400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Psychiatry"],"abstract":"<jats:p>Neurometabolic disorders such as tyrosinemia type 1 (TYRSN1) may interfere with brain metabolism and show symptoms of attention-deficit hyperactivity disorder (ADHD) in patients treated with the enzyme inhibitor nitisinone [2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione, NTBC]. It has been reported that ADHD treatment improves treatment compliance, which is imperative for the long-term prognosis of patients with TYRSN1. In this study, we report the case of a male patient who was diagnosed with TYRSN1 at 3 months of age and was subsequently treated with NTBC, restricted protein intake, and amino acids supplementation. At 7 years of age, he was referred for neuropsychiatric assessment, diagnosed with ADHD, and treated with methylphenidate. The effects of the treatment were monitored via parental interviews, questionnaires covering ADHD symptoms, and a continuous performance test. A reduction in ADHD symptoms, particularly inattentiveness, was observed across all measures. The early identification of ADHD and the treatment of neurometabolic disorders, such as TYRSN1, may be important from a lifetime perspective as this may improve the prognosis of the medical condition as well.<\/jats:p>","DOI":"10.3389\/fpsyt.2023.1213590","type":"journal-article","created":{"date-parts":[[2023,7,18]],"date-time":"2023-07-18T10:06:22Z","timestamp":1689674782000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Case report: ADHD and prognosis in tyrosinemia type 1"],"prefix":"10.3389","volume":"14","author":[{"given":"Helene","family":"Barone","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irene Bircow","family":"Elgen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yngve Thomas","family":"Bliksrud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eirik","family":"Vangs\u00f8y Hansen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rita Rigmor","family":"Skavhellen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Magne Ivar","family":"Furevik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan","family":"Haavik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2023,7,18]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"369","DOI":"10.3109\/00365513.2012.676210","article-title":"Hereditary tyrosinaemia type I in Norway: incidence and three novel small deletions in the fumarylacetoacetase gene","volume":"72","author":"Bliksrud","year":"2012","journal-title":"Scand J Clin Lab Invest."},{"key":"B2","article-title":"The online metabolic and molecular bases of inherited disease","author":"Mitchell","year":"2015"},{"key":"B3","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1007\/s10545-008-0793-1","article-title":"NTBC treatment in tyrosinaemia type I: long-term outcome in French patients","volume":"31","author":"Masurel-Paulet","year":"2008","journal-title":"J Inherit Metab Dis."},{"key":"B4","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1016\/j.neubiorev.2021.11.012","article-title":"symptoms in neurometabolic diseases: underlying mechanisms and clinical implications","volume":"132","author":"Cannon Homaei","year":"2022","journal-title":"Neurosci Biobehav Rev."},{"key":"B5","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1002\/ajmg.b.32764","article-title":"Tyrosinemia Type 1 and symptoms of ADHD: biochemical mechanisms and implications for treatment and prognosis","volume":"183","author":"Barone","year":"2020","journal-title":"Am J Med Genet B Neuropsychiatr Genet."},{"key":"B6","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1007\/978-3-319-55780-9_10","article-title":"Neurological and neuropsychological problems in tyrosinemia type I patients","volume":"959","author":"van Ginkel","year":"2017","journal-title":"Adv Exp Med Biol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1186\/s13023-021-01879-1","article-title":"Treatment adherence in tyrosinemia type 1 patients","volume":"16","author":"Gonzalez-Lamuno","year":"2021","journal-title":"Orphanet J Rare Dis."},{"key":"B8","doi-asserted-by":"crossref","DOI":"10.1176\/appi.books.9780890425596","author":"Association","year":"2013","journal-title":"Diagnostic and Statistical Manual of Mental Disorders"},{"key":"B9","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1176\/ajp.2007.164.6.942","article-title":"The worldwide prevalence of ADHD: a systematic review and metaregression analysis","volume":"164","author":"Polanczyk","year":"2007","journal-title":"Am J Psychiatry."},{"key":"B10","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1192\/bjp.bp.107.048827","article-title":"Prevalence and correlates of adult attention-deficit hyperactivity disorder: meta-analysis","volume":"194","author":"Simon","year":"2009","journal-title":"Br J Psychiatry."},{"key":"B11","doi-asserted-by":"publisher","first-page":"e17","DOI":"10.4088\/JCP.9066tx1c","article-title":"Differential diagnosis of adults with ADHD: the role of executive function and self-regulation","volume":"71","author":"Barkley","year":"2010","journal-title":"J Clin Psychiatry."},{"key":"B12","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1186\/1471-244X-11-128","article-title":"Adult attention deficit hyperactivity disorder is associated with asthma","volume":"11","author":"Fasmer","year":"2011","journal-title":"BMC Psychiatry."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1002\/art.37893","article-title":"Attention deficit and hyperactivity disorder scores are elevated and respond to N-acetylcysteine treatment in patients with systemic lupus erythematosus","volume":"65","author":"Garcia","year":"2013","journal-title":"Arthritis Rheum."},{"key":"B14","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1016\/S2215-0366(21)00171-1","article-title":"Mapping phenotypic and aetiological associations between ADHD and physical conditions in adulthood in Sweden: a genetically informed register study","volume":"8","author":"Du Rietz","year":"2021","journal-title":"Lancet Psychiatry."},{"key":"B15","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1177\/1087054716669589","article-title":"Adult ADHD and comorbid somatic disease: a systematic literature review","volume":"22","author":"Instanes","year":"2018","journal-title":"J Atten Disord."},{"key":"B16","doi-asserted-by":"publisher","first-page":"925442","DOI":"10.3389\/fpsyt.2022.925442","article-title":"Genome guided personalized drug therapy in attention deficit hyperactivity disorder","volume":"13","author":"Haavik","year":"2022","journal-title":"Front Psychiatry."},{"key":"B17","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1023\/B:BOLI.0000028725.37345.62","article-title":"Prevalence of stimulant use for attentional dysfunction in children with phenylketonuria","volume":"27","author":"Arnold","year":"2004","journal-title":"J Inherit Metab Dis."},{"key":"B18","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/gim.2017.101","article-title":"Diagnosis and treatment of tyrosinemia type I: a US and Canadian consensus group review and recommendations","volume":"19","author":"Chinsky","year":"2017","journal-title":"Genet Med"},{"key":"B19","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1007\/s40272-019-00364-4","article-title":"Long-term outcomes and practical considerations in the pharmacological management of tyrosinemia type 1","volume":"21","author":"van Ginkel","year":"2019","journal-title":"Paediatr Drugs."},{"key":"B20","author":"Barkley","year":"1997","journal-title":"Defiant Children: A Clinician\u2018s Manual for Assessment and Parent Training"},{"key":"B21","author":"Knagenhjelm","year":"2010","journal-title":"Quantified Behavioral Test (Qbtest) Technical Manual"},{"key":"B22","author":"Axelson","year":"2009","journal-title":"K-SADS-PL 2009: Working Draft"},{"key":"B23","author":"Norsk","year":"2010","journal-title":"Veileder i Barne-og Undomspsykiatri"},{"key":"B24","first-page":"96","article-title":"Behavioral and intellectual functioning in patients with tyrosinemia type I","volume":"18","author":"Pohorecka","year":"2012","journal-title":"Pediatr Endocrinol Diabetes Metab."},{"key":"B25","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1016\/j.jpeds.2013.10.001","article-title":"Impaired cognitive functioning in patients with tyrosinemia type I receiving nitisinone","volume":"164","author":"Bendadi","year":"2014","journal-title":"J Pediatr."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1001\/jama.2009.1308","article-title":"Evaluating dopamine reward pathway in ADHD: clinical implications","volume":"302","author":"Volkow","year":"2009","journal-title":"J Am Med Assoc."},{"key":"B27","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1037\/0894-4105.17.3.458","article-title":"Timing is everything: executive functions in children exposed to elevated levels of phenylalanine","volume":"17","author":"Antshel","year":"2003","journal-title":"Neuropsychology."},{"key":"B28","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.brainresbull.2013.10.003","article-title":"A comparison of phenylketonuria with attention deficit hyperactivity disorder: do markedly different aetiologies deliver common phenotypes?","volume":"99","author":"Stevenson","year":"2013","journal-title":"Brain Res Bull."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1734","DOI":"10.1542\/peds.2004-1959","article-title":"Attention-deficit\/hyperactivity disorder among adolescents: a review of the diagnosis, treatment, and clinical implications","volume":"115","author":"Wolraich","year":"2005","journal-title":"Pediatrics."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1001\/archpsyc.56.12.1073","article-title":"A 14-month randomized clinical trial of treatment strategies for attention-deficit\/hyperactivity disorder. Multimodal Treatment Study of Children with ADHD","volume":"56","year":"1999","journal-title":"Archiv General Psychiatr"},{"key":"B31","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1177\/1087054708329777","article-title":"Occupational outcome in adult ADHD: impact of symptom profile, comorbid psychiatric problems, and treatment: a cross-sectional study of 414 clinically diagnosed adult ADHD patients","volume":"13","author":"Halmoy","year":"2009","journal-title":"J Atten Disord."},{"key":"B32","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1111\/pedi.12651","article-title":"Previously undiagnosed attention-deficit\/hyperactivity disorder associated with poor metabolic control in adolescents with type 1 diabetes","volume":"19","author":"Nylander","year":"2018","journal-title":"Pediatr Diabetes."},{"key":"B33","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.1007\/s00125-021-05493-5","article-title":"ADHD should be considered in adolescents with type 1 diabetes and poor metabolic control","volume":"64","author":"Nylander","year":"2021","journal-title":"Diabetologia."},{"key":"B34","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1016\/j.biopsych.2013.10.005","article-title":"Effects of methylphenidate on cognitive functions in children and adolescents with attention-deficit\/hyperactivity disorder: evidence from a systematic review and a meta-analysis","volume":"76","author":"Coghill","year":"2014","journal-title":"Biol Psychiatry."},{"key":"B35","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.ejpn.2015.04.004","article-title":"Diagnostic overshadowing in a population of children with neurological disabilities: a cross sectional descriptive study on acquired ADHD","volume":"4","author":"Hendriksen","year":"2015","journal-title":"Eur J Paediatr Neurol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1016\/j.ridd.2010.06.002","article-title":"The ESSENCE in child psychiatry: early symptomatic syndromes eliciting neurodevelopmental clinical examinations","volume":"31","author":"Gillberg","year":"2010","journal-title":"Res Dev Disabil."}],"container-title":["Frontiers in Psychiatry"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2023.1213590\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,18]],"date-time":"2023-07-18T10:06:29Z","timestamp":1689674789000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2023.1213590\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,18]]},"references-count":36,"alternative-id":["10.3389\/fpsyt.2023.1213590"],"URL":"https:\/\/doi.org\/10.3389\/fpsyt.2023.1213590","relation":{},"ISSN":["1664-0640"],"issn-type":[{"value":"1664-0640","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,18]]},"article-number":"1213590"}}